Why this Peninsula company needs a cash fix 2 years after opioid addiction treatment approved

Titan Pharmaceuticals Inc.'s leaders still think — two years after regulatory approval of their drug-device — they can get people off highly addictive opioids. All they need is a little more money. The South San Francisco company (NASDAQ: TTNP) wants to raise $17.9 million to hire a small sales and marketing team to push the use of its impl antable, match stick-sized device that pumps out a continuous flow of the already-approved drug buprenorphine for six months. Buprenorphine, a less-powerful…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news